

Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children

NCT07509047

Status	RECRUITING
Phase	Phase 2
Sponsor	International Vaccine Institute
Enrollment	390 participants

Key Eligibility Criteria

Inclusion (4)

- Individuals aged 1 to 45 years at consent
- Participants/ Participants' legally authorized representative (LAR) willing to provide written informed consent to participate in the study voluntarily
- Participants who can comply with the study requirements
- Individuals in good health as determined by the outcome of medical history, physical examination, and the clinical judgment of the investigator

Exclusion (18)

- Known history or allergy to investigational vaccine components or other medications, or any other allergies
 - Individuals with major congenital abnormalities
 - Known history of immune function disorders including immunodeficiency diseases (known HIV infection or other immune function disorders)
 - Use of systemic steroids within past 6 months (>10 mg/day prednisone equivalent for periods exceeding 2 consecutive weeks), or receive chemotherapy, radiation therapy or other immunosuppressive drugs within the past 6 months.
 - Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives
- ... and 13 more (see full listing online)

Locations (1 total)

KAVI-Institute of Clinical Research, University, Nairobi, Kenyatta National Hospital Complex, Kenya